Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

December 2, 2016December 2, 2016

1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis

News

Protalix BioTherapeutics recently announced that the first patient has been enrolled in the Phase 2 clinical trial evaluating the safety, efficacy and properties of its lead drug candidate, OPRX-106, for the ... Read more

December 1, 2016

Galapagos Starts Phase 3 Trial of Filgotinib for Crohn’s Disease

News

Galapagos, a clinical-stage biotech specializing in small molecule medicines, has dosed its first patient in its DIVERSITY (NCT02914561) Phase 3 clinical trial of filgotinib in Crohn’s disease. The trial is ... Read more

November 30, 2016December 16, 2016

My Love/Hate Relationship with Prednisone

Columns, Crohn's Corner - a column by Judy Walters

I’ve mentioned before that I’ve been on prednisone more than I’ve been off of it for the last few years. My latest stint with this drug started in early September, ... Read more

November 29, 2016November 29, 2016

Researchers Use Blood Test to Identify DNA Changes, Improve Diagnosis in IBD Patients

News

Using a simple blood test from patients with inflammatory bowel diseases (IBD), a team of international researchers were able to identify specific chemical changes in the DNA that could improve the disease diagnosis. ... Read more

November 28, 2016November 28, 2016

Vifor Supports Efforts to Make Public More Aware of Iron Deficiency and Its Health Impact

News

With the 2nd Global Iron Deficiency Day as a backdrop, Vifor Pharma reaffirmed its commitment to supporting health education efforts by leading a series of initiatives to raise awareness of iron ... Read more

November 23, 2016December 16, 2016

When Our Friends Get What We Have, We Must Show Patience

Columns, Crohn's Corner - a column by Judy Walters

So, in the past six months, I’ve had three friends diagnosed with Crohn’s disease or colitis. Considering that so few people, relative to the general population, develop these illnesses, ... Read more

November 18, 2016November 18, 2016

Stelara, Treatment for Moderate-to-Severe Crohn’s Disease, Approved for Use in EU

News

The European Commission (EC) has approved Stelara (ustekinumab) for the treatment of adults with moderate-to-severe Crohn’s disease who had no improvements with other therapies, the drug developer’s, Janssen, announced. Stelara is ... Read more

November 17, 2016

FDA Approves New Test to Help Diagnose IBD, Show it is Different from IBS

News

Inova Diagnostics, a developer of autoimmune diagnostics, announced that the U.S. Food and Drug Administration has cleared QUANTA Lite Calprotectin Extended Range, an assay to diagnose inflammatory bowel disease (IBD) ... Read more

November 16, 2016December 16, 2016

Stressed from sickness, not sick from stress

Columns, Crohn's Corner - a column by Judy Walters

One thing that really gets to me is when people think my mood causes my Crohn’s to flare up. Whenever I say I’m not feeling well, inevitably someone will say, ... Read more

November 15, 2016November 15, 2016

US Patent Issued for Atlantic Healthcare’s Alicaforsen to Treat IBD Pouchitis

News

A U.S. patent has been issued to Atlantic Healthcare’s investigational drug alicaforsen for the treatment of inflammatory bowel disease (IBD). The patent (No. 9453221) extends the use of alicaforsen in IBD-related rectal stump inflammation and ... Read more